ScreenHer

Cover Block

PUBLIC

Attribute	Value
Name	ScreenHer
Tagline	Point-of-care diagnostic platform for non-invasive cervical screening
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences

Data Accuracy: YELLOW -- Company description sourced from its own website [ScreenHer]; core attributes are not independently corroborated by press or databases.

Links

PUBLIC

• Website: https://screen-her.com

Executive Summary

PUBLIC

ScreenHer is a pre-launch healthtech venture developing a point-of-care diagnostic platform for non-invasive cervical screening, a proposition that merits investor attention for its focus on an underserved global health need and its potential to bypass traditional, resource-intensive screening pathways [ScreenHer]. The company's stated mission is to enable earlier cancer detection and improve women's health globally by providing high-sensitivity, same-visit results at the clinic level [ScreenHer]. No founding story, team background, or operational history is publicly documented across major startup databases or press outlets [Perplexity Sonar Pro Brief]. The core technology, described as a diagnostic platform, lacks detailed specifications, and no commercial deployments, clinical validation data, or business model details are available [ScreenHer]. Funding and capitalization are not publicly disclosed, with no confirmed venture rounds or named investors on record [Perplexity Sonar Pro Brief]. Over the next 12-18 months, the primary watchpoints will be the emergence of a founding team with relevant diagnostics or women's health experience, the publication of any preclinical or clinical data, and the securing of initial capital or strategic partnerships to move from concept to development.

Data Accuracy: ORANGE -- Company claims sourced from its website; all other material facts (team, funding, traction) are unverified or absent from public records.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences

Company Overview

PUBLIC

ScreenHer presents a specific challenge for primary-source verification. The entity operating the website screen-her.com describes itself as a point-of-care diagnostic platform for cervical screening, but its corporate identity, founding team, and operational history are not publicly documented in standard startup databases or press archives.

A search for the legal entity "ScreenHer" returns a recent UK incorporation, Screenher Ltd (company #16206873), which was registered in January 2025 [Companies House, Jan 2025]. However, this company's Standard Industrial Classification (SIC) codes are for publishing and television production, indicating it is a distinct entity unrelated to the healthtech platform [Companies House, Jan 2025]. The diagnostic company's jurisdiction of incorporation, headquarters location, and founding date are not disclosed on its website or in any corroborating third-party source.

No funding rounds, named founders, or key operational milestones (such as regulatory submissions, clinical study initiations, or pilot deployments) are cited in available public materials. The company's own website provides a mission statement and product description but offers no chronology of its development [ScreenHer, Unknown].

Data Accuracy: RED -- Based solely on company website claims; no independent verification of corporate existence or milestones.

Product and Technology

MIXED

The company's public-facing description is a single, high-level statement. ScreenHer's website states it is developing a "high-sensitivity, point-of-care diagnostic platform for same-visit, non-invasive cervical screening to detect precancerous and cancerous signals" [ScreenHer]. This positions the product as a hardware-enabled diagnostic tool intended for use in clinical settings, with the goal of delivering results during a single patient visit.

Beyond this mission statement, no further technical details are available in public sources. The platform's underlying technology, development stage, regulatory pathway, and any performance data are not described. The website does not feature product images, technical specifications, or case studies. Similarly, no public announcements regarding clinical trials, partnerships with research institutions, or regulatory submissions (e.g., FDA, CE Mark) have been identified [Perplexity Sonar Pro Brief].

Data Accuracy: ORANGE -- Product claim sourced solely from the company's website; no independent technical validation or corroborating details found.

Market Research and Opportunity

PUBLIC The market for cervical cancer screening is defined by a persistent global need for accessible, high-performance diagnostics, a need that has catalyzed investment in new point-of-care technologies over the last decade.

Available public market sizing focuses on the broader cervical cancer diagnostics segment, which provides a relevant analog. The global market for cervical cancer diagnostics was valued at approximately $8.7 billion in 2023 and is projected to grow at a compound annual rate of 6.5% through 2030, according to a report from Grand View Research [Grand View Research, 2024]. This growth is attributed to rising incidence rates in developing regions and increasing adoption of HPV-based testing in national screening programs. The point-of-care diagnostics segment within this broader market is a smaller but faster-growing category, driven by the push to reduce loss-to-follow-up rates in resource-limited settings.

Demand drivers for a platform like the one described by ScreenHer are well-documented in public health literature. The World Health Organization's global strategy to eliminate cervical cancer, which calls for 70% of women to be screened by 2030, has created a significant policy tailwind for scalable screening solutions [WHO, 2020]. Furthermore, the shift from cytology (Pap smears) to primary HPV testing as the recommended screening method in many high-income countries has opened a window for new diagnostic formats that can use molecular detection at the point of care. Key adjacent markets that influence adoption include the broader women's health diagnostics sector, valued in the tens of billions, and the digital health platforms for clinic management that could integrate such a diagnostic tool.

Regulatory and macro forces present both a pathway and a barrier. Achieving regulatory clearance (e.g., FDA 510(k) or CE Mark) for a novel in-vitro diagnostic is a capital-intensive, multi-year process that defines the commercial timeline for any entrant. In lower-resource settings, procurement is often governed by large tenders from ministries of health or global health organizations, favoring established suppliers with proven scale. However, macro trends like the decentralization of healthcare and the growing investment in women's health technology from both public and private sources are creating a more favorable environment for innovation in this space.

Metric	Value
Global Cervical Cancer Diagnostics (2023)	8.7 $B
Projected CAGR (2024-2030)	6.5 %

The projected steady growth of the core diagnostics market indicates a stable, long-term addressable opportunity, though the more specific point-of-care segment remains a smaller, niche portion of this total. The growth rate suggests incremental evolution rather than disruptive, rapid expansion, placing a premium on efficient market entry and cost-effective scaling for any new platform.

Data Accuracy: YELLOW -- Market sizing is cited from a third-party analyst report, providing a relevant analog. Specific segmentation for point-of-care cervical screening is not publicly available.

Competitive Landscape

MIXED

ScreenHer's competitive positioning is defined by a specific technical ambition, point-of-care cervical screening, but the absence of public commercial or clinical data makes mapping its relative standing against known players a challenge.

Without confirmed named competitors in the structured facts, a direct comparison table is not possible. The analysis must proceed from the category definition. The competitive map for cervical screening is traditionally bifurcated. On one side are established laboratory-based cytology (Pap smear) and molecular testing (HPV DNA) services, offered by large diagnostics corporations like Roche, Hologic, and Quest Diagnostics. These are the incumbents, competing on scale, reimbursement networks, and clinical validation. On the other side are emerging point-of-care and self-sampling technologies aiming to decentralize testing. These include companies developing rapid HPV tests for clinic use and digital colposcopy platforms for visual assessment. ScreenHer's stated focus on a "high-sensitivity, point-of-care diagnostic platform for same-visit" screening places it squarely within this second challenger cohort [ScreenHer].

Where ScreenHer could theoretically claim a defensible edge is in the integration of a non-invasive sampling method with a sensitive, clinic-based readout, aiming to compress the diagnostic timeline from weeks to minutes. This edge, however, is entirely conceptual and perishable without demonstrated clinical performance data, regulatory clearance, or protected intellectual property. The durability of any such advantage would depend on the specificity of its biomarker panel or the proprietary nature of its detection technology, details which are not publicly available. Without these, the edge is vulnerable to replication by better-funded diagnostics firms with established R&D and regulatory pathways.

The company's most significant exposure is its lack of visibility within the commercial and investment landscape of women's health technology. It is absent from major startup databases and press coverage that typically track emerging diagnostic platforms [Perplexity Sonar Pro Brief]. This obscurity suggests it has not yet secured the venture capital or strategic partnerships that would enable it to compete on capital, distribution, or clinical trial scale. A named competitor with a similar point-of-care vision but with published pilot data or venture backing would hold a decisive advantage in talent acquisition, clinician adoption, and regulatory progress.

The most plausible 18-month competitive scenario hinges on validation. If ScreenHer can publicly demonstrate clinical sensitivity and specificity data from a pilot study, it could emerge as a credible contender for early-stage funding and partnership discussions. The winner in such a scenario would be the first mover to combine a validated, clinic-friendly assay with a clear path to regulatory submission. Conversely, if the platform remains in stealth without evidence of technical or commercial progress, it risks being categorized as a conceptual project. The loser would be any entity that fails to transition from a website description to a tangible product in a sector where clinical evidence is the primary currency.

Data Accuracy: YELLOW -- Positioning inferred from company website; competitive mapping based on general category knowledge due to lack of specific named competitor data.

Opportunity

PUBLIC The potential value of ScreenHer, if its core technology performs as described, lies in capturing a meaningful share of the global cervical cancer screening market, which is valued in the billions and burdened by access and compliance challenges.

The headline opportunity for ScreenHer is to become the default point-of-care diagnostic for cervical screening in primary care clinics globally, displacing the traditional, multi-visit Pap smear and HPV testing pathway. This outcome is reachable because the company's stated mission directly addresses two systemic failures in women's health: the need for a same-visit result to improve patient compliance, and the requirement for a platform that can scale outside of centralized labs to reach underserved populations [ScreenHer]. A successful, non-invasive point-of-care test that matches the sensitivity of lab-based methods could redefine the standard of care, making ScreenHer's platform the logical choice for any clinic aiming to increase screening rates.

Growth scenarios outline specific paths to scale. The following table presents two concrete scenarios based on the company's stated target of clinic-based deployment.

Scenario	What happens	Catalyst	Why it's plausible
Public Health Partnership	ScreenHer's platform is adopted by a national or regional public health system in a middle-income country as part of a cervical cancer elimination program.	A successful pilot study demonstrating non-inferiority to standard testing, leading to a government procurement contract.	Public health initiatives are actively seeking scalable, point-of-care solutions to meet WHO elimination targets. The unrelated ScreenHer initiative in Pakistan, which conducted thousands of diabetes screenings in clinics, demonstrates the model and demand for clinic-based women's health programs [Macau Business].
Diagnostic OEM Integration	ScreenHer's detection technology is licensed to a major in-vitro diagnostics (IVD) manufacturer and integrated into their existing global instrument platforms.	Publication of pivotal clinical trial data in a peer-reviewed journal, validating the platform's analytical and clinical performance.	Large IVD companies routinely in-license novel assays to expand their women's health portfolios. A high-sensitivity, point-of-care cervical screening assay would be a strategic addition to any major player's pipeline.

What compounding looks like for ScreenHer would be a classic diagnostic flywheel. Initial clinic adoption generates real-world performance data. This data strengthens the clinical validation dossier, which in turn facilitates regulatory approvals in new geographies. Each new regulatory clearance makes the platform more attractive to larger clinic networks and public health tenders, driving further adoption and generating even more extensive data. This cycle of adoption, data generation, and regulatory expansion could create a significant data and clinical evidence moat, making it progressively harder for new entrants to compete without years of comparable field data.

The size of the win can be framed by looking at comparable transactions and market valuations. For example, the 2021 acquisition of GenMark Diagnostics, a company specializing in multiplex molecular diagnostic systems, by Roche for approximately $1.8 billion provides a benchmark for a platform diagnostics company with proprietary technology [Crunchbase, April 2021]. In a successful Public Health Partnership scenario, where ScreenHer secures a dominant position in a large, protocol-driven market, achieving a valuation in the high hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). The total addressable market is substantiated by the global push for cervical cancer elimination, which creates a sustained, non-discretionary demand for screening tools.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated mission from its website and a comparable market dynamic illustrated by an unrelated screening initiative. Specific financial projections or detailed market share models are not possible with currently available public data.

Sources

PUBLIC

1. [ScreenHer, Unknown] ScreenHER | https://screen-her.com

2. [Companies House, Jan 2025] Screenher Ltd Filing History | https://find-and-update.company-information.service.gov.uk/company/16206873/filing-history

3. [Companies House, Jan 2025] Screenher Ltd | https://find-and-update.company-information.service.gov.uk/company/16206873

4. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief | https://screen-her.com

5. [Grand View Research, 2024] Grand View Research Report | https://www.grandviewresearch.com

6. [WHO, 2020] WHO Global Strategy to Eliminate Cervical Cancer | https://www.who.int/publications/i/item/9789240014107

7. [Macau Business] Macau Business Article | https://macaubusiness.com/advancing-healthcare-access-screenher-initiative-in-pakistan-close-to-reaching-milestone-of-20000-diabetes-screenings-in-70-clinics/

8. [Crunchbase, April 2021] Roche Acquires GenMark Diagnostics | https://www.crunchbase.com/acquisition/roche-acquires-genmark-diagnostics--cc219c84